Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PDSB

PDSB - PDS Biotechnology Corp Stock Price, Fair Value and News

$1.20+0.04 (+3.45%)
Delayed as of 23 Apr 2025, 10:00 am ET
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

PDSB Price Action

Last 7 days

4.5%

Last 30 days

-15.3%

Last 90 days

-30.9%

Trailing 12 Months

-61.2%

PDSB RSI Chart

PDSB Valuation

Market Cap

52.7M

Price/Earnings (Trailing)

-1.4

Price/Sales (Trailing)

59.69

EV/EBITDA

-0.31

Price/Free Cashflow

-1.5

PDSB Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

PDSB Fundamentals

PDSB Revenue

Revenue (TTM)

871.9K

PDSB Earnings

Earnings (TTM)

-37.6M

Earnings Growth (Yr)

27.03%

Earnings Growth (Qtr)

25.86%

PDSB Profitability

EBT Margin

-4447.21%

Return on Equity

-197.9%

Return on Assets

-82.92%

Free Cashflow Yield

-66.58%

PDSB Investor Care

Shares Dilution (1Y)

23.76%

Diluted EPS (TTM)

-1.03

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2018851.3K944.4K917.6K871.9K
2017265.7K385.3K543.3K700.9K
201651.8K99.8K154.5K212.3K
201505.0K7.0K9.1K
2014003.4K2.9K
20130004.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About PDS Biotechnology Corp

PDSB
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. The company is developing various product candidates, which are in preclinical trials, including PDS0102 T-cell receptor gamma alternate reading frame protein (TARP) for treating prostate and breast cancers; PDS0103 (MUC-1) for ovarian, colorectal, lung, and breast cancers; and PDS0104, which include Tyrosinase-related protein 2 for the treatment of melanoma. In addition, it is developing PDS0201 for treating tuberculosis; PDS0202, an influenza vaccine candidate; and PDS0203, a vaccine for the prevention of COVID-19. The company has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is based in Florham Park, New Jersey.
 CEO
 WEBSITEpdsbiotech.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES26

PDS Biotechnology Corp Frequently Asked Questions

What is the ticker symbol for PDS Biotechnology Corp? What does PDSB stand for in stocks?

PDSB is the stock ticker symbol of PDS Biotechnology Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of PDS Biotechnology Corp (PDSB)?

As of Tue Apr 22 2025, market cap of PDS Biotechnology Corp is 52.66 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PDSB stock?

You can check PDSB's fair value in chart for subscribers.

Is PDS Biotechnology Corp a good stock to buy?

The fair value guage provides a quick view whether PDSB is over valued or under valued. Whether PDS Biotechnology Corp is cheap or expensive depends on the assumptions which impact PDS Biotechnology Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PDSB.

What is PDS Biotechnology Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 22 2025, PDSB's PE ratio (Price to Earnings) is -1.4 and Price to Sales (PS) ratio is 59.69. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PDSB PE ratio will change depending on the future growth rate expectations of investors.